Galectin-3 as a Prognostic Biomarker of Left Ventricular Assist Device Implantation Outcomes.

IF 3.1 3区医学 Q2 ENGINEERING, BIOMEDICAL

ASAIO Journal Pub Date : 2024-08-02 DOI:10.1097/MAT.0000000000002292

Ryan Hoang, Mary E Acosta, Mark N Belkin, Nabeel F Rasheed, Umar Siddiqi, Jennifer M Cruz, Sydney E Lupo, Corinne R Stonebraker, Sara Kalantari, Jonathan Grinstein

{"title":"Galectin-3 as a Prognostic Biomarker of Left Ventricular Assist Device Implantation Outcomes.","authors":"Ryan Hoang, Mary E Acosta, Mark N Belkin, Nabeel F Rasheed, Umar Siddiqi, Jennifer M Cruz, Sydney E Lupo, Corinne R Stonebraker, Sara Kalantari, Jonathan Grinstein","doi":"10.1097/MAT.0000000000002292","DOIUrl":null,"url":null,"abstract":"<p><p>We assessed the prognostic potential of Galectin-3 in a sample of 159 heart failure patients who received a left ventricular assist device (LVAD) implant from 2012 to 2020. Clinical outcomes included hemodynamic data, right heart failure (RHF), hemocompatibility-related adverse events (HRAEs), and mortality. Galectin-3 was compounded into Michigan-RVF and EUROMACS-RHF risk scores and compared to the noncompounded risk scores. Right heart failure was significantly correlated with Galectin (p = 0.004) on a continuous spectrum. Inotrope duration was significantly correlated to Galectin-3 (interquartile range [IQR]: 7.58-8.65, p < 0.001) along with INTERMACS score (IQR: 2.14-1.90, p < 0.001). Intensive care unit length of stay (median 8 days, p = 0.02), blood urea nitrogen (p < 0.001), creatinine (p < 0.001), and pulmonary artery pulsatility index (p = 0.05) were also significantly correlated with Galectin-3. In our c-statistic analysis, the predictive value for RHF improved when Galectin-3 was included for both the Michigan-RVF (0.80-0.86) and EUROMACS-RHF (0.77-0.82) risk scores. When elevated over a binary cutoff of 18.2 ng/ml, Galectin-3 significantly correlated with HRAEs (p = 0.014) and mortality (p = 0.031). Galectin-3 shows great promise as a predictive biomarker in patients implanted with durable LVADs. In addition to significant correlation with key clinical outcomes, Galectin-3 enhanced the Michigan-RVF and EUROMACS-RHF risk scores in predicting progression to RHF.</p>","PeriodicalId":8844,"journal":{"name":"ASAIO Journal","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ASAIO Journal","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1097/MAT.0000000000002292","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}

引用次数: 0

Abstract

We assessed the prognostic potential of Galectin-3 in a sample of 159 heart failure patients who received a left ventricular assist device (LVAD) implant from 2012 to 2020. Clinical outcomes included hemodynamic data, right heart failure (RHF), hemocompatibility-related adverse events (HRAEs), and mortality. Galectin-3 was compounded into Michigan-RVF and EUROMACS-RHF risk scores and compared to the noncompounded risk scores. Right heart failure was significantly correlated with Galectin (p = 0.004) on a continuous spectrum. Inotrope duration was significantly correlated to Galectin-3 (interquartile range [IQR]: 7.58-8.65, p < 0.001) along with INTERMACS score (IQR: 2.14-1.90, p < 0.001). Intensive care unit length of stay (median 8 days, p = 0.02), blood urea nitrogen (p < 0.001), creatinine (p < 0.001), and pulmonary artery pulsatility index (p = 0.05) were also significantly correlated with Galectin-3. In our c-statistic analysis, the predictive value for RHF improved when Galectin-3 was included for both the Michigan-RVF (0.80-0.86) and EUROMACS-RHF (0.77-0.82) risk scores. When elevated over a binary cutoff of 18.2 ng/ml, Galectin-3 significantly correlated with HRAEs (p = 0.014) and mortality (p = 0.031). Galectin-3 shows great promise as a predictive biomarker in patients implanted with durable LVADs. In addition to significant correlation with key clinical outcomes, Galectin-3 enhanced the Michigan-RVF and EUROMACS-RHF risk scores in predicting progression to RHF.

查看原文本刊更多论文

作为左心室辅助装置植入术预后生物标志物的Galectin-3

我们对 2012 年至 2020 年期间接受左心室辅助装置（LVAD）植入的 159 例心衰患者样本中 Galectin-3 的预后潜力进行了评估。临床结果包括血液动力学数据、右心衰（RHF）、血液相容性相关不良事件（HRAE）和死亡率。Galectin-3被复合到密歇根-RVF和EUROMACS-RHF风险评分中，并与非复合风险评分进行比较。在连续谱上，右心衰竭与 Galectin 显著相关（p = 0.004）。肌注持续时间与 Galectin-3（四分位数间距 [IQR]：7.58-8.65，p < 0.001）和 INTERMACS 评分（四分位数间距 [IQR]：2.14-1.90，p < 0.001）明显相关。重症监护室的住院时间（中位 8 天，p = 0.02）、血尿素氮（p < 0.001）、肌酐（p < 0.001）和肺动脉搏动指数（p = 0.05）也与 Galectin-3 显著相关。在我们的 c 统计学分析中，当密歇根-RVF（0.80-0.86）和 EUROMACS-RHF （0.77-0.82）风险评分中包含 Galectin-3 时，RHF 的预测值有所提高。当 Galectin-3 升高超过 18.2 ng/ml 的二元临界值时，它与 HRAEs（p = 0.014）和死亡率（p = 0.031）显著相关。Galectin-3 很有希望成为植入耐久性 LVAD 患者的预测性生物标志物。除了与主要临床结果有明显相关性外，Galectin-3 还增强了密歇根-RVF 和 EUROMACS-RHF 风险评分在预测 RHF 进展方面的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ASAIO Journal 医学-工程：生物医学

CiteScore

6.60

自引率

7.10%

发文量

651

审稿时长

4-8 weeks

期刊介绍： ASAIO Journal is in the forefront of artificial organ research and development. On the cutting edge of innovative technology, it features peer-reviewed articles of the highest quality that describe research, development, the most recent advances in the design of artificial organ devices and findings from initial testing. Bimonthly, the ASAIO Journal features state-of-the-art investigations, laboratory and clinical trials, and discussions and opinions from experts around the world. The official publication of the American Society for Artificial Internal Organs.